Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

@inproceedings{Jones2010ComparisonOT,
  title={Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study},
  author={Graeme Jones and Anthony I Sebba and Jieruo Gu and Mitchell B Lowenstein and Armando Calvo and Juan J G{\'o}mez-Reino and Didier Siri and Matija Tom{\vs}i{\vc} and Emma Alecock and Thasia E Woodworth and Mark C Genovese},
  booktitle={Annals of the rheumatic diseases},
  year={2010}
}
BACKGROUND The anti-interleukin (IL) 6 receptor antibody tocilizumab inhibits signalling of IL6, a key cytokine in rheumatoid arthritis (RA) pathogenesis. OBJECTIVE To evaluate through the AMBITION study the efficacy and safety of tocilizumab monotherapy versus methotrexate in patients with active RA for whom previous treatment with methotrexate… CONTINUE READING